EGFR and colorectal cancer: FXR antagonist activity of secondary BAs has been demonstrated, indicating that these compounds are positive effectors of colorectal cancer progression.35,36 However, taurine-conjugated cholic acid-induced proliferation has been reported through phosphorylation of Src, EGFR, and ERK 1/2, while unconjugated BAs act through FXR-dependent mechanisms, inactivating the EGFR, Src, and ERK proteins, thereby inhibiting proliferation.37 These contradictory results can be explained by differences in the concentrations of BA to which cells were exposed in the studies.